Skip to main content
SpringerLink
Log in

Pharmacotherapy of Stress Urinary Incontinence

  • Chapter
Continence

  • 870 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hunskaar S, Burgio K, Diokno, et al. 2002:Epidemiology and natural history of urinary incontinence. In Abrams P, Cardozo L, Khoury S, et al., eds. Incontinence. Health Publication Ltd. Plymouth, UK: 165–201.

    Google Scholar 

  2. Hunskaar S, Burgio K, Clark A,. et al. 2005: Epidemiology of urinary (UI) and faecal (FI) incontinence and pelvic organ prolapse. In: Abrams P, Cardozo L, Khoury S, Wein A eds. Incontinence, Vol. I: Basics and evaluation. Health Publication Ltd. Plymouth, UK: 255–312.

    Google Scholar 

  3. DeLancey JOL. 1997; The pathophysiology of stress urinary incontinence in women and its implications for surgical treatment. World J Urol 15:(5)268–274.

    Article  PubMed  CAS  Google Scholar 

  4. Henriksson L, Anderson. K-E, Ulmsten U. 1979; The urethral pressure profiles in continent and stress incontinent women. Scand J Urol Nephrol 13:(1)5–10.

    Article  Google Scholar 

  5. Hilton P, Stanton SL. 1983; Urethral pressure measurement by microtransducer: The results in symptom-free women and in those with genuine stress incontinence. Br J Obstet Gynaecol 90:(10)919–933.

    Article  PubMed  CAS  Google Scholar 

  6. Anderson KE, Appell R, Caardozo L,. et al. 2005: Pharmacological treatment of urinary incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence: 3rd International Consultation on Incontinence. Health publication Ltd. Plymouth, UK: 809–854.

    Google Scholar 

  7. Versi E, Cardozo L. 1988.Estrogens and the lower urinary tract function. Blackwell Scientific, London:

    Google Scholar 

  8. Hodson BJ, Dumas S, Bolling DR,. et al. 1978; Effect of estrogen on sensitivity of rabbit bladder and urethra to phenylephrine. Invest Urol 16 (1):67–69.

    Google Scholar 

  9. Larsson B, Andersson KJ, Batra S,. et al. 1984; Effect of estradiol on norepinephrine-induced contraction, alpha adrenorecptor number and norepinephrine content in the female rabbit uretra. J Pharmacol Exp Ther 229:557–563.

    PubMed  CAS  Google Scholar 

  10. Moehrer B, Hextall A, Jackson S. 2003.Oestrogens for urinary incontinence in women (Cochrane Review). In: The Cochrane Library,. Issue 4Wiley, Chichester, UK:

    Google Scholar 

  11. Grady D, Brown JS, Vittinghoff E,. et al. 2001; Postmenopausal hormones and incontinence: The Heart and Estrogen/Progestin Replacement Study. Obstet Gynecol 97:(1)116–120.

    Article  PubMed  CAS  Google Scholar 

  12. Al-Badr A. Ross A, Soroka D,. et al. 2003; What is the available evidence for hormone replacement therapy in women stress urinary incontinence. J Obstet Gynecol Can 25:(7)567–574.

    Google Scholar 

  13. Hendrix SL, Cochrane BB, Nygaard IE, et al. 2005; Effects of estrogen with and without progestin on urinary incontinence. JAMA 293(8):998–1001.

    Article  Google Scholar 

  14. Brune ME, O’Neill AB, Gauvin DM,. et al. 2001; Comparison of alpha 1-adrenoceptor agonists in canine urethral pressure profilometry and abdominal leak point pressure models. J Urol 166:(4)1555–1559.

    Article  PubMed  CAS  Google Scholar 

  15. Diokno AC, Taub M. 1975; Ephedrine in treatment of urinary incontinence. Urology 5:(5)624–625.

    Article  PubMed  CAS  Google Scholar 

  16. Collste L, Lindskog M. 1987; Phenylpropanolamine in treatment of female stress urinary incontinence: Double-blind placebo controlled study in 24 patients. Urology 30:(4)398–403.

    Article  PubMed  CAS  Google Scholar 

  17. Siltberg H, Larsson G, Hallen B,. et al. 1999; Validation of cough-induced leak point pressure measurement in the evaluation of pharmacological treatment of stress incontinence. Neurourol Urodyn 18:(6)591–602.

    Article  PubMed  CAS  Google Scholar 

  18. Zinner NR, Koke SC, Viktrup L. 2004;Pharmacotherapy for stress urinary incontinence. Present and future options. Drugs 64:(14)1503–1516.

    Article  PubMed  Google Scholar 

  19. Fleming G. 2000; The FDA regulation and the risk of stroke. N Engl J Med 343:(25)1886–1887.

    Article  PubMed  CAS  Google Scholar 

  20. Anderson KW, Appell R, Awad S,. et al. 2002:Pharmacological treatment of urinary incontinence. In: Abrams P, Khoury S, Wein A eds. Incontinence. Health Publications Ltd.Plymouth, UK: 418–511.

    Google Scholar 

  21. Weil EH, Eerdmans PH, Dijkman GA,. et al. 1998; Randomized double-blind placebo-controlled multicenter evaluation of efficacy and dose finding of midodrine hydrochloride in women with mild to moderate stress urinary incontinence: A phase II study. Int Urogynecol J Pelvic Floor Dysfunct 9:(3)145–150.

    Article  PubMed  CAS  Google Scholar 

  22. Radley SC, Chapple CR, Bryan NP, et al. 2001; Effect of methoxamine on maximum urethral pressure in women with genuine stress incontinence: A placebo-controlled, double-blind crossover study. Neurourol Urodyn 20:(1)43–52.

    Article  PubMed  CAS  Google Scholar 

  23. Blue DR. 2003; Pharmacological characteristics of Ro 115–1240, a selective . α1A/1L-adrenoceptor partial agonist: A potential therapy for stress urinary incontinence BJU Int93:164–172.

    Google Scholar 

  24. Musselman DM, Ford APDW, Gennevois DJ,. et al. 2004; A randomized crossover study to evaluate Ro 115–1240, a selective a1A/1L-adrenoceptor partial agonist in women with stress urinary incontinence. BJU Int. 93:(1)78–83).

    Article  PubMed  CAS  Google Scholar 

  25. Script. World Pharmaceutical News. April 28th, 2004. No. 2947.

    Google Scholar 

  26. Kaisary AV. 1984; Beta adrenoceptor blockade in the treatment of female urinary stress incontinence. J Urol (Paris) 90:(5)351–353.

    CAS  Google Scholar 

  27. Ishiko O, Ushiroyama T, Saji F,. et al. 2000; Beta2.-adrenergic agonists and pelvic floor exercises for female stress incontinence Int J Gynaecol Obstet 71:(1)39–44.

    Article  PubMed  CAS  Google Scholar 

  28. Yasuda K, Kawabe K, Takimoto Y,. et al. 1993; A double-blind clinical trial of a beta2-adrenergic agonist in stress incontinence. Int Urogynecol J 4:146–151.

    Article  Google Scholar 

  29. Hunsballe JM, Djurhuus JC. 2001; Clinical options for imipramine in the management of urinary incontinence. Urol Res 29:(2)118–125.

    Article  PubMed  CAS  Google Scholar 

  30. Gilja I, Radej M, Kovacic M,. et al. 1984; Conservative treatment of female stress incontinence with imipramine. J Urol 132:(5)909–911.

    PubMed  CAS  Google Scholar 

  31. Lin HH, Sheu BC, Lo MC,. et al. 1999; Comparison of treatment outcomes for imipramine for female genuine stress incontinence. Br J Obstet Gynaecol 106:(10)1089–1092.

    Article  PubMed  CAS  Google Scholar 

  32. Frazer A. 1997; Pharmacology of antidepressants. J Clin Psychopharmacol 17:(Suppl 1)2s–18s.

    Article  PubMed  CAS  Google Scholar 

  33. Thor KB, Katofiasc MA. 1995; Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthesized female cat. J Pharmacol Exp Ther 274:1014–1024.

    PubMed  CAS  Google Scholar 

  34. Katofiasc MA, Nissen J, Audia JE, Thor KB. 2002; Comparison of the effects of serotonin selective, norpepinephrine selective, and dual serotonin and norepinephrine reuptake inhibitors on lower urinary tract function in cats. Life Sci 71:1227–1236.

    Article  PubMed  CAS  Google Scholar 

  35. Bymaster FP, Dresfield-Ahmad LJ, Threlkeld PG, et al. 2001; Comparative affinity of duloxetine and venlafaxine for serotonin and norpepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25:(6)871–880.

    Article  PubMed  CAS  Google Scholar 

  36. Michel MC, Oelke M, 2005; Duloxetine in the treatment of stress urinary incontinence. Women’s Health 1:(3)345–358.

    PubMed  CAS  Google Scholar 

  37. Norton PA, Zinner NR, Yalcin I, Bump RC. 2002; Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol 187:(1)40–48.

    Article  PubMed  CAS  Google Scholar 

  38. Dmochowski RR, Miklos JR, Norton PA, et al. 2003; Duloxetine versus placebo for the treatment of non-American women with stress urinary incontinence. J Urol 170:1259–1263.

    Article  PubMed  CAS  Google Scholar 

  39. van Kerrebroeck, Abrams P, Lange R, et al. 2004; Duloxetine vs. placebo in the treatment of European and Canadian women with stress urinary incontinence. BJOG 11:249–257.

    Google Scholar 

  40. Millard RJ, Moore K, Rencken R,. et al. 2004; for the Duloxetine Study Group. Duloxetine vs. placebo in the treatment of stress urinary incontinence: A four-continent randomized clinical trial. BJUI 93:3111–318.

    Article  Google Scholar 

  41. Cardozo L, Drutz HP, Baygani SK, Bump RC. 2004; Pharmacological treatment of women awaiting surgery for stress urinary incontinence. Obstet Gynecol. 104:(3)511–519.

    Article  PubMed  CAS  Google Scholar 

  42. Castro-Diaz D, Palma PC, Bouchard C,. et al. 2007; Effect of dose escalation on the tolerability and efficacy of duloxetine in the treatment of women with stress urinary incontinence. Int Urogynecol J Pelvic Floor Disfunct 18:919–929.

    Article  Google Scholar 

  43. Mallinckrodt C, Goldstein DJ, Detke MJ,. et al. 2003:Duloxetine: A long term treatment for the emotional and physical symptoms of depression. Primary Care Companion J Clin Psych 5:19–28.

    Article  Google Scholar 

  44. Ghoniem GM, Van Leeuwen JS, Elser DM, et al. 2005;A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence. J Urol 173:(5)1647–1653.

    Article  PubMed  CAS  Google Scholar 

  45. Bump RC, Bent AE, Gousse AE, et al. 2006; Duloxetine treatment of women with mixed urinary incontinence (MUI). (IUGA) [abstract No. 31]. Int Urogynecol J 17:(Suppl 2)S57–S100.

    Google Scholar 

  46. Bump R, Steers W, Herschorn S, et al. Duloxetine compared with placebo for the treatment of women with symptoms of bladder overactivity. International Continence Society, 36th Annual Meeting. Abstract No. 127.

    Google Scholar 

  47. Hua TC, Pan A, Chan C, et al. Effect of duloxetine on tolterodine pharmacokinetics in healthy volunteers. BJ Clin Pharm 57(5):652.

    Google Scholar 

  48. Skinner MH, Kuan HY, Skerjanec A,. et al. 2004; Effect of age on the pharmacokinetics of duloxetine in women. BJ Clin Pharm 57:(1)54.

    Article  CAS  Google Scholar 

  49. Viktrup L, Yalcin I. 2007; Duloxetine treatment of stress urinary incontinence in women: Effects of demographics, obesity, chronic lung disease, hypoestrogenism, diabetes mellitus and depression on efficacy. Eur J Obstet Gynecol Reprod Biol. 133:105–113.

    Article  PubMed  CAS  Google Scholar 

  50. Castro-Diaz D, Pascual MA. 2005; Pharmacotherapy for stress urinary incontinence. Curr Opin Urol 15:(4)227–230.

    Article  PubMed  Google Scholar 

  51. Schlenker B, Gratzke C, Reich O,. et al. 2006; Preliminary results of the off-label use of duloxetine for the treatment of stress incontinence after radical prostatectomy or cystectomy. Eur Urol 49:1075–1078.

    Article  PubMed  CAS  Google Scholar 

  52. Chapple CR. 2006; Duloxetine for male stress incontinence. Eur Urol 49:958–960.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University Hospital of the Canary Islands, Tenerife, Spain

    David Castro-Diaz

Authors
  1. David Castro-Diaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sergio Fumero
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Urology, Wake Forest University Baptist Medical Center, Winston Salem, NC, USA

    Gopal H. Badlani MD

  2. Department of Gynecology, Cleveland Clinic Florida, Weston, FL, USA

    G. Willy Davila MD

  3. Department of Pharmacology and Pharmacotherapy Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

    Martin C. Michel MD, MAE

  4. Department of Urology Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

    Jean J. M. C. H. de la Rosette MD, PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag London Limited

About this chapter

Cite this chapter

Castro-Diaz, D., Fumero, S. (2009). Pharmacotherapy of Stress Urinary Incontinence. In: Badlani, G.H., Davila, G.W., Michel, M.C., de la Rosette, J.J.M.C.H. (eds) Continence. Springer, London. https://doi.org/10.1007/978-1-84628-510-3_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-84628-510-3_8

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84628-510-3

  • Online ISBN: 978-1-84628-734-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation